<DOC>
	<DOCNO>NCT00480064</DOCNO>
	<brief_summary>A multicenter randomize trial perform compare induction therapy ( IC : Idarubicin Cytarabine , 5+7 ) ICL ( drug plus lomustine ( CCNU ) , 200mg\m2 orally day 1 ) . Patients complete remission ( CR ) randomize receive either maintenance therapy intensification intermediate-dose cytarabine idarubicin follow maintenance therapy .</brief_summary>
	<brief_title>Lomustine Intermediate Dose Cytarabine Older Patients With AML</brief_title>
	<detailed_description>Induction therapy : Patients randomize receive idarubicin plus cytarabine ( IC ) drug plus lomustine ( ICL ) , latter give dose 200 mg/m2 orally day 1 . Patients persistent leukemia bone marrow , define least 20 % marrow cellularity 5 % blast day 14 subsequent time point follow initiation induction therapy , receive second course induction chemotherapy identical initial induction course . Non-responders second induction course take protocol . Consolidation therapy : After complete induction treatment , patient complete remission 1 2 induction course receive course consolidation ( IC ’ ) therapy idarubicin subcutaneous cytarabine . Subsequently , stable remission persist , patient receive maintenance therapy maintenance therapy precede second consolidation ( IIC ) intermediate-dose cytarabine . Randomization perform soon CR achieve . Maintenance therapy : This conducted patient persist CR one month complete first ( IC ) second ( IIC ) consolidation consist follow : five course combination chemotherapy 1 , 3 , 6 , 9 13 month last consolidation , namely cytarabine ( subcutaneously ) idarubicin course one year : continuous regimen methotrexate 6-mercaptopurine , alternate 10 day-courses .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Patients age 60 year old de novo AML accord FAB criterion With normal cardiac function leave ventricular ejection fraction &gt; = 50 % , absence unstable cardiac arrhythmia unstable angina . Unimpaired renal ( creatinin &lt; 180µmol\L ) Unimpaired liver ( bilirubin &lt; 35µmol\L ) function . Performance status &lt; 3 Signed date informed consent . Acute promyelocytic leukemia Patients myeloproliferative syndrome prior diagnosis AML Patients previously myelodysplastic syndrome Patients pretreated chemo radiotherapy Performance status &lt; 2 Positive serology HIV</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>AML</keyword>
	<keyword>old patient</keyword>
	<keyword>lomustine</keyword>
</DOC>